Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme - Jacob, S; Bain, S; Réa, R; Warren, M; Holst, A; Vrazic, H; Madsbad, S (Diabetologie und Stoffwechsel, 2019)